Loading the section…

BEAM: financial statements from SEC — TradeAlmanac

BEAM

Beam Therapeutics Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	31/03/2026	30/09/2025	30/06/2025	31/03/2025	30/09/2024	30/06/2024
Revenue	32M	10M	8M	7M	14M	12M
Research and development	105M	110M	102M	99M	94M	87M
Selling, general and administrative	34M	27M	27M	28M	27M	30M
Operating expenses	139M	137M	129M	127M	121M	117M
Operating income	−107M	−127M	−120M	−119M	−107M	−105M
Pre-tax income	—	−113M	−102M	—	−97M	−91M
Income tax	—	—	—	—	—	39,000
Net income	−94M	−113M	−102M	−109M	−97M	−91M
Earnings per share	−0.91	−1.10	−1.00	−1.24	−1.17	−1.11
Earnings per share, diluted	−0.91	−1.10	−1.00	−1.24	−1.17	−1.11
Weighted average shares	103M	103M	102M	88M	82M	82M
Weighted average shares, diluted	103M	103M	102M	88M	82M	82M

Balance sheet

Metric	31/03/2026	31/12/2025	30/09/2025	30/06/2025	31/03/2025	31/12/2024	30/09/2024	30/06/2024
Cash and equivalents	288M	295M	268M	282M	528M	282M	230M	293M
Short-term investments	923M	950M	807M

Cash flow

Metric	31/03/2026	31/03/2025
Operating cash flow	−129M	−104M
Depreciation and amortisation	6M	6M
Share-based compensation	19M	27M
Capital expenditure	2M	3M
Investing cash flow	25M	−125M
Financing cash flow	97M

Amounts in USD unless stated otherwise. Data: US exchange trading and company filings with the regulator